Measurement of the patients' general health status with the RAND 36-Item Health Survey largely corroborated the results found with the Seattle Angina Questionnaire.
Nearly 25% of the follow-up assessments were not available for analysis, but the investigators performed sensitivity analyses, which did not detect any potential biases.
Dr. Peterson reported receiving consulting fees from Bayer and Pfizer Inc., and grant support from Sanofi-Aventis, Bristol-Myers Squibb Co., Schering-Plough Corp., and Merck & Co. Dr. Rumsfeld disclosed that he is a scientific advisory board member at UnitedHealthcare and is chief science officer of the National Cardiovascular Data Registry.
Dr. Weintraub and some of his coinvestigators reported financial ties to a variety of pharmaceutical companies, which provided funding for the trial. The U.S. Department of Veterans Affairs Cooperative Studies Program and the Canadian Institutes of Health Research also funded the study.
Percutaneous coronary intervention is not always essential for the relief of stable angina symptoms. DR. PETERSON
ELSEVIER GLOBAL MEDICAL NEWS